

Matteo Molica

List of Publications by Citations

Source: <https://exaly.com/author-pdf/665656/matteo-molica-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

79
papers

692
citations

15
h-index

21
g-index

83
ext. papers

832
ext. citations

3.4
avg, IF

4.09
L-index

#	Paper	IF	Citations
79	Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment. <i>Annals of Hematology</i> , 2015 , 94, 393-7	3	47
78	How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review. <i>Leukemia Research</i> , 2014 , 38, 1392-8	2.7	33
77	Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC). <i>Supportive Care in Cancer</i> , 2015 , 23, 3289-95	3.9	31
76	Ponatinib: A Review of Efficacy and Safety. <i>Current Cancer Drug Targets</i> , 2018 , 18, 847-856	2.8	26
75	SARS-CoV-2 infection anxieties and general population restrictions delay diagnosis and treatment of acute haematological malignancies. <i>British Journal of Haematology</i> , 2020 , 190, e5-e8	4.5	24
74	Maintenance therapy in AML: The past, the present and the future. <i>American Journal of Hematology</i> , 2019 , 94, 1254-1265	7.1	24
73	Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. <i>Leukemia Research</i> , 2014 , 38, 1173-6	2.7	22
72	Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?. <i>Annals of Hematology</i> , 2014 , 93, 1951-2	3	22
71	Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2010 , 85, 314-20	3.8	22
70	Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2007 , 31, 1575-8	2.7	21
69	Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. <i>American Journal of Hematology</i> , 2018 , 93, E159-E161	7.1	19
68	Vitamin D insufficiency predicts time to first treatment (TFT) in early chronic lymphocytic leukemia (CLL). <i>Leukemia Research</i> , 2012 , 36, 443-7	2.7	19
67	Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option. <i>Clinical Drug Investigation</i> , 2018 , 38, 475-476	3.2	15
66	Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocytic leukemia cells. <i>Annals of Hematology</i> , 2014 , 93, 1819-23	3	15
65	Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontline. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 107, 190-198	7	14
64	Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. <i>Annals of Hematology</i> , 2018 , 97, 1797-1802	3	14
63	Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia. <i>Therapeutic Advances in Hematology</i> , 2019 , 10, 2040620719826444	5.7	13

62	Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. <i>International Journal of Cardiology</i> , 2020 , 301, 163-166	3.2	13
61	Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib. <i>American Journal of Hematology</i> , 2015 , 90, E100-1	7.1	12
60	Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a real-life patient population with chronic myeloid leukaemia. <i>Hematological Oncology</i> , 2017 , 35, 232-236 ¹⁻³	1.3	11
59	Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response. <i>Leukemia and Lymphoma</i> , 2016 , 57, 99-102	1.9	11
58	The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017 , 92, E661-E664 ¹	7.1	11
57	Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN. <i>Annals of Hematology</i> , 2017 , 96, 387-391	3	11
56	Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia. <i>International Journal of Hematology</i> , 2008 , 88, 374-380	2.3	11
55	Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. <i>Annals of Hematology</i> , 2019 , 98, 1885-1890	3	10
54	Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update. <i>Expert Review of Molecular Diagnostics</i> , 2017 , 17, 1001-1008	3.8	10
53	Systematic review of dasatinib in chronic myeloid leukemia. <i>OncoTargets and Therapy</i> , 2013 , 6, 257-65	4.4	10
52	Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib. <i>Oncotarget</i> , 2018 , 9, 7534-7540	3.3	10
51	Early molecular response in chronic myeloid leukemia and halving time: Latest evidences. <i>Leukemia Research</i> , 2016 , 48, 20-5	2.7	9
50	Monoclonal B-cell lymphocytosis: a reappraisal of its clinical implications. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1660-5	1.9	9
49	Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice. <i>Annals of Hematology</i> , 2019 , 98, 1919-1925	3	8
48	Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy. <i>Expert Review of Hematology</i> , 2018 , 11, 301-306	2.8	8
47	Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 525-33	4.1	8
46	Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib. <i>American Journal of Hematology</i> , 2015 , 90, 105-8	7.1	8
45	Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2009 , 83, 208-14	3.8	8

44	Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events. <i>Annals of Hematology</i> , 2018 , 97, 1803-1808	3	8
43	Second line small molecule therapy options for treating chronic myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 57-65	4	7
42	Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life. <i>Annals of Hematology</i> , 2019 , 98, 1891-1904	3	7
41	Clinical relevance and treatment of nonautoimmune anemia in chronic lymphocytic leukemia. <i>Cancer Management and Research</i> , 2011 , 211	3.6	7
40	How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes. <i>Expert Review of Hematology</i> , 2017 , 10, 155-159	2.8	6
39	Long-term outcome of chronic myeloid leukaemia patients with p210 and p190 co-expression at baseline. <i>British Journal of Haematology</i> , 2015 , 169, 148-50	4.5	5
38	Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2206-7	1.9	5
37	Current first- and second-line treatment options in acute promyelocytic leukemia. <i>International Journal of Hematologic Oncology</i> , 2016 , 5, 105-118	1	5
36	Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib. <i>British Journal of Haematology</i> , 2016 , 173, 945-6	4.5	5
35	Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors. <i>British Journal of Haematology</i> , 2018 , 182, 427-429	4.5	5
34	Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life. <i>American Journal of Hematology</i> , 2017 , 92, E668-E670	7.1	4
33	A review of current induction strategies and emerging prognostic factors in the management of children and adolescents with acute lymphoblastic leukemia. <i>Expert Review of Hematology</i> , 2020 , 13, 755-769	2.8	4
32	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019 , 98, 889-896	3	4
31	Treatment-free remission in chronic myeloid leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2019 , 17, 686-696	0.6	4
30	Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid. <i>British Journal of Haematology</i> , 2014 , 167, 428-30	4.5	3
29	Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1621-30	4	3
28	Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome. <i>Blood Transfusion</i> , 2014 , 12 Suppl 1, s162-3	3.6	3
27	Clinical relevance and treatment of nonautoimmune anemia in chronic lymphocytic leukemia. <i>Cancer Management and Research</i> , 2011 , 3, 211-7	3.6	3

26	Prognostic Significance of Transcript-Type in Chronic Myeloid Leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020 , 12, e2020062	3.2	3
25	The role of cladribine in acute myeloid leukemia: an old drug up to new tricks. <i>Leukemia and Lymphoma</i> , 2020 , 61, 536-545	1.9	3
24	Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib. <i>British Journal of Haematology</i> , 2018 , 181, 275-278	4.5	2
23	Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?. <i>European Journal of Haematology</i> , 2018 , 101, 578	3.8	2
22	Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>American Journal of Hematology</i> , 2015 , 90, E181-2	7.1	2
21	Drug treatment options for acute promyelocytic leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 1-11	4	2
20	Updated review of nilotinib as frontline treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia. <i>Clinical Investigation</i> , 2015 , 5, 257-265		1
19	Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors. <i>Blood</i> , 2018 , 132, 3006-3006	2.2	1
18	Treatment free remission in chronic myeloid leukemia: Lights and shadows. <i>Hematology Reports</i> , 2020 , 12, 8950	0.9	1
17	Life-Threatening Autoimmune Hemolytic Anemia and Idiopathic Thrombocytopenic Purpura. Successful Selective Splenic Artery Embolization. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016 , 8, e2016020	3.2	1
16	Incidence of Clinically Significant (≥ 10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib. <i>Oncology Research and Treatment</i> , 2019 , 42, 660-664	2.8	0
15	Incidence of Severe (≥ 10 g/dl) Chronic Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib and Role of Erythropoietin Therapy. <i>Blood</i> , 2016 , 128, 1903-1903 ²	2.2	0
14	Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance. <i>Leukemia and Lymphoma</i> , 2020 , 61, 3476-3483	1.9	0
13	Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients. <i>American Journal of Hematology</i> , 2015 , 90, E95-6	7.1	
12	The Importance of Body Surface Area at Baseline and during Treatment in Chronic Myeloid Leukemia Patients Treated with Imatinib. <i>Acta Haematologica</i> , 2015 , 134, 57-8	2.7	
11	Validation of a new proposed relapse risk score (CBC-score) for acute promyelocytic leukaemia. <i>International Journal of Hematology</i> , 2014 , 99, 100-1	2.3	
10	Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?. <i>Blood</i> , 2018 , 132, 1746-1746	2.2	
9	Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice. <i>Blood</i> , 2018 , 132, 5518-5518	2.2	

8	Overall Survival and Response Rates after a 10-Year Follow-up of Chronic Myeloid Leukemia Patients in Chronic Phase Treated with Imatinib in a Real-Life Practice. <i>Blood</i> , 2018 , 132, 1741-1741	2.2
7	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of Who 2001 Versus Who 2008/2016 Criteria in a Large Single Center Cohort. <i>Blood</i> , 2018 , 132, 5464-5464	2.2
6	Systematic Coronary Risk Evaluation (SCORE) Chart Identify Chronic Myeloid Leukemia Patients at Risk of Cardiovascular Diseases during Nilotinib Treatment. <i>Blood</i> , 2014 , 124, 4545-4545	2.2
5	Impact of Comorbidities and Body Mass Index in Myelofibrosis Patients Treated with Ruxolitinib: A Retrospective Analysis. <i>Blood</i> , 2016 , 128, 5464-5464	2.2
4	Clinical Relevance of an Extended Diagnostic Work-Out in Patients with Primary Autoimmune Amolytic Anemia (AIHA). <i>Blood</i> , 2012 , 120, 3192-3192	2.2
3	Case Report: Very Late, Atypical Extra-Medullary Relapse in a Patient With Acute Promyelocytic Leukemia (APL) Rescued With a Transplant-Free Approach. <i>Frontiers in Oncology</i> , 2021 , 11, 699886	5.3
2	Clinical characteristics and outcome of patients with autoimmune hemolytic anemia uniformly defined as primary by a diagnostic work-up. <i>American Journal of Hematology</i> , 2016 , 91, E319-20	7.1
1	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, e328-e333	2